Share on LinkedInShare on LinkedIn

ARTICLE · 16 JULY 2026

FTC Secures Record USD12 Million Penalty For HSR Avoidance: Lessons From The Edwards/Genesis Settlement

A&O Shearman
A&O Shearman
Contributor

A&O Shearman

Introducing A&O Shearman Unparalleled global depth for a changing world. Today more than ever,...

View firm profile
Explore more from A&O Shearman

On July 13, 2026, the Department of Justice and the Federal Trade Commission (FTC) (together, the “Agencies”) resolved allegations that Edwards Lifesciences Corp. (“Edwards”) intentionally structured its acquisition...

United StatesAntitrust/Competition Law

On July 13, 2026, the Department of Justice and the Federal Trade Commission (FTC) (together, the “Agencies”) resolved allegations that Edwards Lifesciences Corp. (“Edwards”) intentionally structured its acquisition of JC Medical Inc. (“JC Medical”) from Genesis MedTech Group Limited (“Genesis”) to evade the notification and waiting-period requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”).1 The settlement imposes a combined USD12m penalty on the parties and is the largest fine ever imposed for failing to make an HSR filing.

Edwards’ acquisition of JC Medical was structured with two components. On July 22, 2024, Edwards acquired JC Medical from Genesis for USD115m, then subsequently acquired USD25m of non-voting shares in Genesis on August 9, 2024.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from